Connecting you with your industry every day
A bombshell announcement from two industry high-flyers was kept completely under wraps despite multiple big-name organisations getting on board with the new pharma venture. And now, they've detailed a potentially market-disrupting business model for medicines access
New research commissioned by Pfizer Australia exposes near-universal public support for expanding the PBS among Coalition, Labor, Greens and One Nation voters
Last week saw a string of medicines registered on the ARTG, including two heart drugs, a new contraceptive option, and Novo’s hyped obesity pill
Five months after leaving Arrotex, the former Novartis Country President ANZ is launching his own Sydney-headquartered pharma company with another high-profile exec as Co-Founder
He knows plenty about the role, having served as interim Managing Director for six months, now this leader has officially landed the top job, providing certainty for the pharma as it navigates a changing reimbursement landscape
AstraZeneca leader joins board to promote trade between Europe and Australia bolstering collaboration, innovation and investment
This company will now be a specialty pharma focused on the United States with its Australian assets moving to new hands for $55M
Three drugs were removed and another added in a last-minute revision to the agenda for the PBAC's last three-day meeting for 2026
Mega license agreement inked with Chinese powerhouse covering six antibody-drug conjugate and T-cell engager programs
While RRMS is a PBS success story with Australians having the best access to meds in the world, there are new drugs coming that also need to be funded
Four organisations have been selected to provide comprehensive genomic profiling for 25,000 Australians in the next phase of this screening program
More than four in 10 clinicians say conversations with reps are mostly about products but what they'd really like to discuss is this...
An update to the TGA's prescription medicines under evaluation list shows 11 drug applications were accepted in August, signalling what could enter the Australian market next year
Potential first-in-class treatment for a disease with high unmet need falls at the finish line of a pivotal trial after this pharma paid a hefty price in July
The hardline UK industry watchdog is at it again, slapping a company with 11 breaches of the Code over a single webpage on a Congress website after a complaint from an ex-employee which described the company's missteps as an embarrassment to the industry
The MFN isn't going anywhere soon, and the Commonwealth will need to adjust its pricing expectations if it wants Australians to gain access to the latest medicines
The number of blockbuster drugs have skyrocketed, with a new report taking a deep dive into whether industry can sustain the boom in the face of looming patent cliffs
The first oral GLP-1 drug has been approved for use in Australia for weight loss and will likely hit the private market this year, with a rival hot on its heels
Just months after undergoing a major rebrand, this Australian biotech is embarking on its next phase of growth, with plans to establish a US subsidiary
The decision came despite a high-priority recommendation from its Advisory Group with the current fiscal environment and constraints of the public health system to blame
The UK pharma giant has announced a "reshaping" programme which will see jobs lost in some areas but gained in others
A drug currently seeking to unlock broader government subsidy in Australia was crowned one of the best products of 2026 at the Prix Galien USA awards
South Australian researchers have described one of Novartis' fastest-growing brands as "a huge step forward" in frontline treatment options
In the latest round of job moves, industry leaders move up alongside long-timers changing companies - one after almost 30 years working at the same pharma
So that's where he's gone... Well-known Aussie pharma exec has been tapped for a global position, joining a new company at a time of significant growth
TGA wins its case against a company which unlawfully advertised prescription-only medicines, which the judge described as a "deliberate commercial strategy"
AdvanCell has challenged two patent application by a Norwegian company that cover the production of the radioisotope used in its flagship product
After this drug wowed ESMO last month Australian researchers have discovered another combo that could disrupt treatment for small cell lung cancer